389058-62-2

Basic information

• Product Name: 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(3-methoxyphenyl)amino]-1,3-dimethyl-
• CAS NO: 389058-62-2
• Molecular Formula: C16H17N5O2
• Molecular Weight: 311.343
• Mol File: 389058-62-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(3-methoxyphenyl)amino]-1,3-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(3-methoxyphenyl)amino]-1,3-dimethyl-(389058-62-2)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(3-methoxyphenyl)amino]-1,3-dimethyl-(389058-62-2)

Safety Data

• Hazardous Substances Data: 389058-62-2(Hazardous Substances Data)

Upstream product

• 175201-94-2 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 175201-95-3 4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl chloride 
• 20481-33-8 diethyl 2-{[(1,3-dimethyl-1H-pyrazol-5-yl)amino]methylene}malonate 
• 20481-15-6 ethyl 4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridine-5-carboxylate 
• 3524-32-1 5-Amino-1,3-dimethylpyrazole 
• 536-90-3 m-Anisidine 
• 175201-98-6 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 

Relevant articles and documents

New orally active PDE4 inhibitors with therapeutic potential

Structural optimization of pyrazolopyridine derivative 2, which is one of the newly discovered chemical leads for PDE4 inhibitors from our in-house library, was carried out successfully. The process of discovery of new orally active PDE4 inhibitors, which

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.